AI stocks like Nvidia, Super Micro Computer, and Dell Technologies are leading the market but may be in bubble territory. Value stocks like W.P. Carey and Bristol Myers Squibb offer beaten-down prices...
Bristol Myers has delivered some underwhelming returns for investors in the past decade. The company's future is uncertain as it faces multiple patent cliffs....
Fragile stagflation presents challenges for investors, with limited opportunities for good returns in stocks and bonds. It is likely markets will experience a lost decade in real terms when measured f...
The pharmaceutical market is a critical part of the healthcare industry. It contributes largely to research, development, production and distribution of important life-saving vaccines and medications....
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects....
Bristol Myers Squibb stock (NYSE: BMY) currently trades at $42 per share, 47% below its pre-inflation shock high of $80 seen in June 2022. In contrast, its peer – Merck stock – is up 56% over this...
In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $42.19, denoting a -0.09% change from the preceding trading day....
Bristol Myers (BMY) wins FDA approval for Krazati, in combination with Erbitux, as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer...
Income-oriented investors love finding dividend stocks to buy now. That's particularly true when those stocks are on sale, as many continue to be....
AstraZeneca should have lots of growth ahead. Bristol Myers Squibb has what it takes to navigate a major patent cliff....
Pfizer has a lot of new drugs on the market, but its stock has been beaten down. Johnson & Johnson stock is down even though both its medical technology and pharmaceutical businesses reported signific...